Prevention/Epidemiology Africa: New Vaginal Ring Borrows From Birth Control to Fight AIDSJune 10, 2010 The International Partnership for Microbicides (IPM) is launching the first clinical trial in Africa of a vaginal ring to help combat HIV infection. The double-blind, randomized, placebo-controlled trials of the ring will occur at research centers in southern and eastern Africa. The rings contain 25 mg of the new antiretroviral drug dapivirine. Existing vaginal rings, in contrast, contain contraceptive or therapeutic hormones. Recent World Health Organization data show that HIV/AIDS is the leading cause of death globally in women 15 to 44 years old. In Africa, it is the single most important cause of disease for women ages 15-59. The purpose of these studies is to measure the acceptability of the vaginal ring and whether it will be used correctly. "You have to make sure that a product is acceptable before you test its efficacy, because if people don't like the product, what's the point?" said Pamela Norick, a spokesperson for IPM. Dapivirine is in the same class of antiretrovirals as those used to reduce mother-to-child HIV transmission. If the new vaginal rings prove safe and acceptable to users, they will be further studied for efficacy. If all goes well, they could be marketed by 2015, according to Zeda Rosenberg, a top official at IPM. "Vaginal rings have tremendous promise because they could offer discreet, effective and sustained protection against HIV infection," IPM said in a statement. Agence France Presse 06.08.2010 This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |